
Successful cellular therapy depends on careful coordination and on understanding how the major platforms differ.

Successful cellular therapy depends on careful coordination and on understanding how the major platforms differ.

Cellular therapy for advanced melanoma is delivered at authorized treatment centers, which makes timely referral from community oncologists essential.

PRAME, a tumor-associated antigen highly expressed in melanoma with limited expression in healthy tissue, has become an increasingly attractive target for vaccines, engineered T-cell therapies, and bispecific agents

Immune checkpoint inhibitors have transformed frontline care for metastatic melanoma, but a substantial proportion of patients do not achieve durable disease control, which leaves a clear unmet need after progression.

James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.

September 15th 2015